Shares of Zydus Lifesciences rose 2 percent in early trade on March 14 after the company launched cancer drug Olaparib, a PARP inhibitor, under the brand name IBYRA in India.
At 9:20am, Zydus Lifesciences was quoting Rs 985.70, up Rs 17.00, or 1.75 percent, on the BSE.
The drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for more tailored and effective treatment approach.
Among cancer patients in India, those who are diagnosed as HRD positive or with BRACA mutation need to be administered this PARP inhibitor which can delay the progression of the disease.
IBYRA is a next-gen targeted therapy for HRD positive and BRACA positive cancer patients.
Catch all market action in our live blog
To help identify the right patients and facilitate access, Zydus has collaborated with MedGenome for comprehensive HRD testing. This alongwith a year-long treatment of IBYRA has been capped at Rs 3 lakh as compared to the cost of around Rs 72 lakh by the innovator.
“For patients newly diagnosed with these specific cancers, the right diagnosis and the right treatment early on can give them a big advantage in the fight against cancers. Our patient support focus in launching IBYRA helps them with both cutting-edge diagnosis for HRD positive cancer and precision therapy in the most affordable way. We believe this will reduce the disease burden for the patients in a significant way," said Dr Sharvil Patel, managing director of Zydus Lifesciences.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
